• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CEM-102（夫西地酸）对流行克隆和耐表型金黄色葡萄球菌的体外活性。

In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus.

机构信息

Eurofins Medinet, Chantilly, Virginia, USA.

出版信息

Antimicrob Agents Chemother. 2013 Sep;57(9):4535-6. doi: 10.1128/AAC.00206-13. Epub 2013 Jun 17.

DOI:10.1128/AAC.00206-13
PMID:23774441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3754304/
Abstract

Clinical development of CEM-102 (fusidic acid) has recently begun in the United States for chronic oral treatment of prosthetic joint infections. To support this development, the in vitro activity of fusidic acid against important Staphylococcus aureus clones and resistance phenotypes was determined. Against 51 such isolates, the modal fusidic acid MIC was 0.12 μg/ml (range, 0.06 to 0.25 μg/ml for 49 isolates). This level of in vitro fusidic acid activity underscores the potential clinical utility of this compound in the United States.

摘要

CEM-102（夫西地酸）的临床开发最近已在美国开始，用于慢性口服治疗人工关节感染。为了支持这一发展，测定了夫西地酸对重要金黄色葡萄球菌克隆和耐药表型的体外活性。对 51 株此类分离株进行检测，夫西地酸的中值 MIC 为 0.12μg/ml（49 株分离株的范围为 0.06 至 0.25μg/ml）。这种体外夫西地酸活性水平突出了该化合物在美国的潜在临床应用。

相似文献

1
In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus.CEM-102（夫西地酸）对流行克隆和耐表型金黄色葡萄球菌的体外活性。
Antimicrob Agents Chemother. 2013 Sep;57(9):4535-6. doi: 10.1128/AAC.00206-13. Epub 2013 Jun 17.
2
Dissemination of fusidic acid resistance among Staphylococcus aureus clinical isolates.金黄色葡萄球菌临床分离株中夫西地酸耐药性的传播。
BMC Microbiol. 2015 Oct 13;15:210. doi: 10.1186/s12866-015-0552-z.
3
In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin.瑞他帕林对耐夫西地酸和莫匹罗星的金黄色葡萄球菌分离株的体外活性
J Antimicrob Chemother. 2008 Oct;62(4):766-8. doi: 10.1093/jac/dkn266. Epub 2008 Jun 19.
4
In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.体外抗微生物研究发现，美国 2008-2009 年收集的当代革兰阳性菌对夫西地酸有反应。
Clin Infect Dis. 2011 Jun;52 Suppl 7:S477-86. doi: 10.1093/cid/cir163.
5
Activity of fusidic acid against extracellular and intracellular Staphylococcus aureus: influence of pH and comparison with linezolid and clindamycin.夫西地酸对细胞外和细胞内金黄色葡萄球菌的活性：pH 值的影响及与利奈唑胺和克林霉素的比较。
Clin Infect Dis. 2011 Jun;52 Suppl 7:S493-503. doi: 10.1093/cid/cir165.
6
Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.金黄色葡萄球菌临床菌血症分离株中对夫西地酸耐药性的遗传决定因素。
Antimicrob Agents Chemother. 2009 May;53(5):2059-65. doi: 10.1128/AAC.00871-08. Epub 2009 Mar 16.
7
Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates.金黄色葡萄球菌临床分离株中夫西地酸耐药决定因子。
Antimicrob Agents Chemother. 2010 Dec;54(12):4985-91. doi: 10.1128/AAC.00523-10. Epub 2010 Sep 20.
8
Fusidic acid resistance in Staphylococcus aureus nasal carriage strains in nine European countries.九个欧洲国家金黄色葡萄球菌鼻腔携带菌株中的夫西地酸耐药性
Future Microbiol. 2014;9(6):737-45. doi: 10.2217/fmb.14.36.
9
Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008.2007-2008 年北美和澳大利亚分离的金黄色葡萄球菌中夫西地酸耐药率和耐药机制的流行情况。
Antimicrob Agents Chemother. 2010 Sep;54(9):3614-7. doi: 10.1128/AAC.01390-09. Epub 2010 Jun 21.
10
Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk diffusion, and Etest methods as applied to Staphylococcus aureus.检测试剂中夫西地酸（CEM-102）药敏性表现：应用于金黄色葡萄球菌的肉汤微量稀释法、纸片扩散法和 E 试验法。
J Clin Microbiol. 2010 Mar;48(3):972-6. doi: 10.1128/JCM.01829-09. Epub 2010 Jan 6.

引用本文的文献

1
The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics.结核分枝杆菌介导的靶向外源化学物代谢的意义。
Nat Rev Chem. 2023 May;7(5):340-354. doi: 10.1038/s41570-023-00472-3. Epub 2023 Mar 20.
2
Crystal Structure of Elongation Factor G1.延伸因子G1的晶体结构
Front Mol Biosci. 2021 Sep 3;8:667638. doi: 10.3389/fmolb.2021.667638. eCollection 2021.
3
The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.全球临床分离金黄色葡萄球菌中夫西地酸耐药的流行情况：系统评价和荟萃分析。
Antimicrob Resist Infect Control. 2021 May 1;10(1):75. doi: 10.1186/s13756-021-00943-6.
4
Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in Static and Dynamic Models.抗葡萄球菌抗生素与夫西地酸联合应用对静态和动态模型中葡萄球菌生物膜的活性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00598-18. Print 2018 Jul.
5
Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.夫西地酸：一种用于口服治疗急慢性葡萄球菌感染的细菌延伸因子抑制剂。
Cold Spring Harb Perspect Med. 2016 Jan 4;6(1):a025437. doi: 10.1101/cshperspect.a025437.

本文引用的文献

1
A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.一项随机、双盲的 2 期研究比较了口服夫西地酸负荷剂量方案与口服利奈唑胺治疗急性细菌性皮肤和皮肤结构感染的疗效和安全性。
Clin Infect Dis. 2011 Jun;52 Suppl 7:S520-6. doi: 10.1093/cid/cir167.
2
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.药代动力学-药效学模型的应用及新型夫西地酸给药方案的合理性：使拉撒路复活。
Clin Infect Dis. 2011 Jun;52 Suppl 7:S513-9. doi: 10.1093/cid/cir166.
3
In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.体外抗微生物研究发现，美国 2008-2009 年收集的当代革兰阳性菌对夫西地酸有反应。
Clin Infect Dis. 2011 Jun;52 Suppl 7:S477-86. doi: 10.1093/cid/cir163.
4
Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008.2007-2008 年北美和澳大利亚分离的金黄色葡萄球菌中夫西地酸耐药率和耐药机制的流行情况。
Antimicrob Agents Chemother. 2010 Sep;54(9):3614-7. doi: 10.1128/AAC.01390-09. Epub 2010 Jun 21.
5
Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.首次报告耐利奈唑酮的金黄色葡萄球菌爆发与 cfr 基因介导的利奈唑酮耐药有关。
Clin Infect Dis. 2010 Mar 15;50(6):821-5. doi: 10.1086/650574.
6
Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.评估针对来自美国和加拿大的当代革兰阳性临床分离株进行的夫西地酸活性测试。
Int J Antimicrob Agents. 2010 Mar;35(3):282-7. doi: 10.1016/j.ijantimicag.2009.10.023. Epub 2009 Dec 29.
7
Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.耐甲氧西林金黄色葡萄球菌菌株中的抗生素耐药性不断增加。
Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S360-7. doi: 10.1086/533592.
8
Staphylococci.葡萄球菌
Int J Antimicrob Agents. 2007 May;29 Suppl 3:S23-32. doi: 10.1016/S0924-8579(07)72175-1.
9
Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus.耐夫西地酸金黄色葡萄球菌流行欧洲克隆株引起的脓疱病的特征分析
J Clin Microbiol. 2007 May;45(5):1505-10. doi: 10.1128/JCM.01984-06. Epub 2007 Mar 7.
10
Genetic basis of resistance to fusidic acid in staphylococci.葡萄球菌对夫西地酸耐药性的遗传基础。
Antimicrob Agents Chemother. 2007 May;51(5):1737-40. doi: 10.1128/AAC.01542-06. Epub 2007 Feb 26.